The National Cancer Institute (NCI) estimates that only approximately 3% of US adult cancer patients participate in clinical trials. The low participation rate is a major bottleneck in developing new cancer treatments. Clearly a key factor in progress toward better treatment and prognosis in adult oncology lies in improving participation rates.
Learn more about improving participation rates in adult oncology trials through the use of: